aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
September 11, 2023 08:00 ET
|
aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application
March 01, 2023 08:00 ET
|
aTyr Pharma, Inc.
Proof-of-Concept study in SSc-ILD expected to begin in 2023. Efzofitimod has been granted U.S. FDA orphan drug designation for SSc and Fast Track designation for SSc-ILD. SAN DIEGO, March 01, 2023 ...
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
November 09, 2022 08:00 ET
|
aTyr Pharma, Inc.
First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. ...
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
October 11, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines...
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
September 27, 2022 08:00 ET
|
aTyr Pharma, Inc.
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. ...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
September 13, 2022 08:00 ET
|
aTyr Pharma, Inc.
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE)...
aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022
September 01, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
August 15, 2022 16:00 ET
|
aTyr Pharma, Inc.
First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
August 11, 2022 08:03 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of...